Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Small molecule heparanase inhibitors as anti-metastatic cancer drugs

Project description

Advancing heparanase inhibitors for metastatic cancer therapy

Many cancers express elevated levels of the heparanase enzyme known to degrade extracellular matrix and facilitate cancer cell invasion, metastasis and angiogenesis. Heparanase also contributes to immune evasion and chemoresistance, making it a promising target for cancer therapy. Several heparanase inhibitors have entered clinical trials, demonstrating promise in treating haematologic and solid malignancies. The ERC-funded HEPARANIB project aims to investigate the potential of novel heparanase inhibitors for metastatic cancer treatment. Researchers will optimise synthesis of small molecules and conduct initial pharmacokinetic and pharmacodynamic studies. Inhibitors will be evaluated in breast cancer, lung cancer and multiple myeloma models, and promising candidates will be promoted for clinical testing.

Objective

The Heparanib Proof-of-Concept project aims to establish the feasibility of our unique small molecule heparanase inhibitors as drug candidates for the treatment of metastatic cancers. To strengthen our science case (experimental development A) and by building on our in vivo data in mouse models for metastatic breast cancer, lung cancer and multiple myeloma, we will (A-I) design a suitable route of synthesis to prepare sufficient quantities of clinical grade material; (A-II) synthesise reference compounds; and (A-III) perform initial pharmacokinetics/pharmacodynamics (PK/PD) studies. With the aim to prepare for the establishment of a spin-out biotech company (business development B) to take our leads towards the clinic we will (B-IV) strengthen our intellectual property (IP) position; (B-V) perform an extensive analysis of the anti-metastatic cancer drug market; and (B-VI) prepare for commercialisation by consolidating the results in an investor-ready business plan to develop and commercialise our anticancer drug candidate.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-POC2

See all projects funded under this call

Host institution

UNIVERSITEIT LEIDEN
Net EU contribution
€ 150 000,00
Address
RAPENBURG 70
2311 EZ Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)